Arthrocentesis for Knee Osteoarthritis

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Jason Jennings, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Colorado Joint Replacement

No Placebo Group

Trial Summary

What is the purpose of this trial?

This will be prospective study of patients with knee effusion associated with degenerative osteoarthritis or symptomatic primary total knee arthroplasty that undergo therapeutic joint arthrocentesis. The diagnosis of knee osteoarthritis will be based on knee radiographs (including AP, Rosenburg view, lateral and Merchant views) read and interpreted by one of our clinical providers (PA, Fellow or Surgeon). Patients with at least Grade II Kellgren and Lawrence changes or higher will be included in the osteoarthritis group. Patients in the arthroplasty group must have had a primary total knee arthroplasty without infection (as determined by knee aspirate) to be included. Patients will be clinically evaluated at the time of their visit for presence of a knee effusion using a stroke test and graded on a 5-point scale (zero, trace, 1+, 2+, or 3+) which has shown good interrater reliability. Patients with a mild to severe effusion (1+ to 3+) will considered for the study. Patients having significant pain associated with their effusion will be offered a therapeutic arthrocentesis as part of their treatment plan discussion. This is a pre-post test design in which outcome measures will be collected immediately pre-arthrocentesis and immediately post arthrocentesis. Additionally, there will be an optional 7-10 follow up visit where outcomes measures will be collected again, should the participant choose to return to this visit.

Research Team

Jason Jennings, MD

Principal Investigator

Colorado Joint Replacement

Eligibility Criteria

Inclusion Criteria

Patients aged 18 years or older with mild (1+) to severe (3+) knee effusion associated with underlying osteoarthritis (Kellgren and Lawrence grade II or higher) that undergo therapeutic aspiration

Patients with symptomatic primary total knee arthroplasty without infection (as verified by prior aspiration) with moderate to severe effusion electing for therapeutic arthrocentesis. Must be minimum of 3 months from index surgery to be included.

Exclusion Criteria

Patients with knee effusion associated with septic arthritis or periprosthetic knee infection as determined from knee arthrocentesis

You have a type of arthritis that causes inflammation, such as JIA, RA, or psoriatic arthritis.

You have a pre-existing condition affecting your muscles, like stroke, cerebral palsy, multiple sclerosis, or muscular dystrophy.

Treatment Details

Interventions

• Arthrocentesis (Procedure)

Participant Groups

Group I: Primary TKA Experimental Treatment 1 Intervention

Patients with total knee replacements will participate in this arm.

Group II: Primary Osteoarthritis Experimental Treatment 1 Intervention

Patients with native knees and effusions will participate in this arm.

Who Is Running the Clinical Trial?

Colorado Joint Replacement

Lead Sponsor

Trials

13

Recruited

3,300+